Randolf J. Kerschbaumer

1.0k total citations
30 papers, 707 citations indexed

About

Randolf J. Kerschbaumer is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Cellular and Molecular Neuroscience. According to data from OpenAlex, Randolf J. Kerschbaumer has authored 30 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 13 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Cellular and Molecular Neuroscience. Recurrent topics in Randolf J. Kerschbaumer's work include Macrophage Migration Inhibitory Factor (17 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Nuclear Receptors and Signaling (8 papers). Randolf J. Kerschbaumer is often cited by papers focused on Macrophage Migration Inhibitory Factor (17 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Nuclear Receptors and Signaling (8 papers). Randolf J. Kerschbaumer collaborates with scholars based in Austria, United States and Germany. Randolf J. Kerschbaumer's co-authors include Gottfried Himmler, Dirk Völkel, Friedrich Scheiflinger, Gerhard Antoine, Hans Peter Schwarz, Klaus F. Zimmermann, Barbara Plaimauer, Bernhard Lämmle, Miha Furlan and Friedrich Scheiflinger and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Randolf J. Kerschbaumer

30 papers receiving 669 citations

Peers

Randolf J. Kerschbaumer
Kazuo Ohnishi Japan
Nobuko Kawasaki Japan
Odile Letourneur France
Shmuel Cabilly Israel
P B Lønblad Denmark
Kavita Mistry United States
Vijaya L. Simhadri United States
V K Chaudhary United States
Martin Fugère Canada
Regina Haars Germany
Kazuo Ohnishi Japan
Randolf J. Kerschbaumer
Citations per year, relative to Randolf J. Kerschbaumer Randolf J. Kerschbaumer (= 1×) peers Kazuo Ohnishi

Countries citing papers authored by Randolf J. Kerschbaumer

Since Specialization
Citations

This map shows the geographic impact of Randolf J. Kerschbaumer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randolf J. Kerschbaumer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randolf J. Kerschbaumer more than expected).

Fields of papers citing papers by Randolf J. Kerschbaumer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randolf J. Kerschbaumer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randolf J. Kerschbaumer. The network helps show where Randolf J. Kerschbaumer may publish in the future.

Co-authorship network of co-authors of Randolf J. Kerschbaumer

This figure shows the co-authorship network connecting the top 25 collaborators of Randolf J. Kerschbaumer. A scholar is included among the top collaborators of Randolf J. Kerschbaumer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randolf J. Kerschbaumer. Randolf J. Kerschbaumer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kerschbaumer, Randolf J., et al.. (2024). Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer. Molecular Cancer Therapeutics. 23(9). 1219–1229. 1 indexed citations
2.
Maurer, Barbara, et al.. (2023). Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic. Molecular Cancer Therapeutics. 22(5). 555–569. 7 indexed citations
3.
Ferhat, Maroua, Katia Mangano, Randolf J. Kerschbaumer, et al.. (2023). The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis. European Journal of Pharmacology. 956. 175997–175997. 3 indexed citations
4.
5.
Douillard, Patrice, Michael Freissmuth, Gerhard Antoine, et al.. (2019). Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and Pharmacokinetics. Antibodies. 8(3). 46–46. 6 indexed citations
6.
Baumgartner, Bernhard, Barbara Dietrich, Patrice Douillard, et al.. (2017). Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis. European Journal of Pharmacology. 820. 206–216. 5 indexed citations
7.
Mahalingam, Devalingam, Manish R. Patel, Jasgit C. Sachdev, et al.. (2016). Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study. Annals of Oncology. 27. vi116–vi116. 3 indexed citations
8.
Mahalingam, Devalingam, Manish R. Patel, Jasgit C. Sachdev, et al.. (2016). Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors. Cancer Research. 76(14_Supplement). CT046–CT046. 1 indexed citations
9.
Freissmuth, Michael, Dirk Völkel, Michael Thiele, et al.. (2013). Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo. Molecular Cancer Therapeutics. 12(7). 1223–1234. 59 indexed citations
10.
Kerschbaumer, Randolf J., Manfred Rieger, Dirk Völkel, et al.. (2012). Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the β-Sheet Structure of MIF. Journal of Biological Chemistry. 287(10). 7446–7455. 51 indexed citations
11.
Scheiflinger, F., Michael Dockal, Jan Rosing, & Randolf J. Kerschbaumer. (2008). Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies. Journal of Thrombosis and Haemostasis. 6(2). 315–322. 6 indexed citations
12.
Kerschbaumer, Randolf J., et al.. (2004). An Antibody Specific for Coagulation Factor IX Enhances the Activity of the Intrinsic Factor X-activating Complex. Journal of Biological Chemistry. 279(39). 40445–40450. 7 indexed citations
13.
Zimmermann, Klaus F., Meinhard Hasslacher, Randolf J. Kerschbaumer, et al.. (2004). Mutation of the surface‐exposed amino acid Trp2313 to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional protein. British Journal of Haematology. 125(5). 629–637. 14 indexed citations
14.
Kerschbaumer, Randolf J., et al.. (2003). Higher expression of fab antibody fragments in a CHO cell line at reduced temperature. Biotechnology and Bioengineering. 84(4). 433–438. 52 indexed citations
15.
16.
17.
Griep, Remko A., Charlotte van Twisk, Randolf J. Kerschbaumer, et al.. (1999). pSKAP/S: An Expression Vector for the Production of Single-Chain Fv Alkaline Phosphatase Fusion Proteins. Protein Expression and Purification. 16(1). 63–69. 44 indexed citations
18.
Kerschbaumer, Randolf J., Angelika Ziegler, Graham H. Cowan, et al.. (1997). A scFv-alkaline phosphatase fusion protein which detects potato leafroll luteovirus in plant extracts by ELISA. Journal of Virological Methods. 63(1-2). 237–242. 36 indexed citations
19.
Kerschbaumer, Randolf J., et al.. (1997). Single-Chain Fv Fusion Proteins Suitable as Coating and Detecting Reagents in a Double Antibody Sandwich Enzyme-Linked Immunosorbent Assay. Analytical Biochemistry. 249(2). 219–227. 68 indexed citations
20.
Kerschbaumer, Randolf J., et al.. (1996). pDAP2: a vector for construction of alkaline phosphatase fusion-proteins. Immunotechnology. 2(2). 145–150. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuo Ohnishi Breakdown of academic impact, for papers by Nobuko Kawasaki Breakdown of academic impact, for papers by Odile Letourneur Breakdown of academic impact, for papers by Shmuel Cabilly Breakdown of academic impact, for papers by P B Lønblad Breakdown of academic impact, for papers by Kavita Mistry Breakdown of academic impact, for papers by Vijaya L. Simhadri Breakdown of academic impact, for papers by V K Chaudhary Breakdown of academic impact, for papers by Martin Fugère Breakdown of academic impact, for papers by Regina Haars
Rankless by CCL
2026